RT Journal Article
SR Electronic
T1 Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.06.15.21258542
DO 10.1101/2021.06.15.21258542
A1 RECOVERY Collaborative Group
A1 Horby, Peter W
A1 Mafham, Marion
A1 Peto, Leon
A1 Campbell, Mark
A1 Pessoa-Amorim, Guilherme
A1 Spata, Enti
A1 Staplin, Natalie
A1 Emberson, Jonathan R
A1 Prudon, Benjamin
A1 Hine, Paul
A1 Brown, Thomas
A1 Green, Christopher A
A1 Sarkar, Rahuldeb
A1 Desai, Purav
A1 Yates, Bryan
A1 Bewick, Tom
A1 Tiberi, Simon
A1 Felton, Tim
A1 Baillie, J Kenneth
A1 Buch, Maya H
A1 Chappell, Lucy C
A1 Day, Jeremy N
A1 Faust, Saul N
A1 Jaki, Thomas
A1 Jeffery, Katie
A1 Juszczak, Edmund
A1 Lim, Wei Shen
A1 Montgomery, Alan
A1 Mumford, Andrew
A1 Rowan, Kathryn
A1 Thwaites, Guy
A1 Weinreich, David M
A1 Haynes, Richard
A1 Landray, Martin J
YR 2021
UL http://medrxiv.org/content/early/2021/06/16/2021.06.15.21258542.abstract
AB Background REGEN-COV is a combination of 2 monoclonal antibodies (casirivimab and imdevimab) that bind to two different sites on the receptor binding domain of the SARS-CoV-2 spike protein. We aimed to evaluate the efficacy and safety of REGEN-COV in patients admitted to hospital with COVID-19.Methods In this randomised, controlled, open-label platform trial, several possible treatments were compared with usual care in patients hospitalised with COVID-19. Eligible and consenting patients were randomly allocated (1:1) to either usual standard of care alone (usual care group) or usual care plus a single dose of REGEN-COV 8g (casirivimab 4g and imdevimab 4g) by intravenous infusion (REGEN-COV group). The primary outcome was 28-day mortality assessed first among patients without detectable antibodies to SARS-CoV-2 at randomisation (seronegative) and then in the overall population. The trial is registered with ISRCTN (50189673) and clinicaltrials.gov (NCT04381936).Findings Between 18 September 2020 and 22 May 2021, 9785 patients were randomly allocated to receive usual care plus REGEN-COV or usual care alone, including 3153 (32%) seronegative patients, 5272 (54%) seropositive patients and 1360 (14%) patients with unknown baseline antibody status. In the primary efficacy population of seronegative patients, 396 (24%) of 1633 patients allocated to REGEN-COV and 451 (30%) of 1520 patients allocated to usual care died within 28 days (rate ratio 0·80; 95% CI 0·70-0·91; p=0·0010). In an analysis involving all randomised patients (regardless of baseline antibody status), 944 (20%) of 4839 patients allocated to REGEN-COV and 1026 (21%) of 4946 patients allocated to usual care died within 28 days (rate ratio 0·94; 95% CI 0·86-1·03; p=0·17). The proportional effect of REGEN-COV on mortality differed significantly between seropositive and seronegative patients (p value for heterogeneity = 0·001).Interpretation In patients hospitalised with COVID-19, the monoclonal antibody combination of casirivimab and imdevimab (REGEN-COV) reduced 28-day mortality among patients who were seronegative at baseline.Funding UK Research and Innovation (Medical Research Council) and National Institute of Health Research (Grant ref: MC_PC_19056).Competing Interest StatementDavid M Weinreich is Senior Vice President, Global Clinical Development, Regeneron Pharmaceuticals Inc. and holds stock/stock options in Regeneron Pharmaceuticals. No other authors have competing interests. Clinical TrialThe trial is registered with ISRCTN (50189673) and clinicaltrials.gov (NCT04381936).Clinical Protocols https://www.recoverytrial.net Funding StatementUK Research and Innovation (Medical Research Council) and National Institute of Health Research (Grant ref: MC_PC_19056). Casirivimab/imdevimab (REGEN-COV2) was provided free of charge by Regeneron Pharmaceuticals Inc.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The trial is conducted in accordance with the principles of the International Conference on Harmonisation-Good Clinical Practice guidelines and approved by the UK Medicines and Healthcare products Regulatory Agency (MHRA) and the Cambridge East Research Ethics Committee (ref: 20/EE/0101).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe protocol, consent form, statistical analysis plan, definition & derivation of clinical characteristics & outcomes, training materials, regulatory documents, and other relevant study materials are available online at www.recoverytrial.net. As described in the protocol, the trial Steering Committee will facilitate the use of the study data and approval will not be unreasonably withheld. Deidentified participant data will be made available to bona fide researchers registered with an appropriate institution within 3 months of publication. However, the Steering Committee will need to be satisfied that any proposed publication is of high quality, honours the commitments made to the study participants in the consent documentation and ethical approvals, and is compliant with relevant legal and regulatory requirements (e.g. relating to data protection and privacy). The Steering Committee will have the right to review and comment on any draft manuscripts prior to publication. Data will be made available in line with the policy and procedures described at: https://www.ndph.ox.ac.uk/data-access. Those wishing to request access should complete the form at https://www.ndph.ox.ac.uk/files/about/data_access_enquiry_form_13_6_2019.docx and e-mailed to: data.access@ndph.ox.ac.uk https://www.ndph.ox.ac.uk/data-access